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Abstract 
Purpose: Urine Cytology has been a longstanding first line investigation for haematuria 
and is recommended in current major guidelines. Objectives are to determine the 
contribution of urine cytology in haematuria investigations and its cost implications  
Materials and Methods: Data prospectively collected for 2778 consecutive patients 
investigated for haematuria at a UK teaching hospital January 1999 to September 2007 
with final analysis in October 2010. All patients underwent standard haematuria 
investigations; urine cytology, flexible cystoscopy and renal tract US with IVU or CTU 
performed for visible haematuria patients without diagnosis following first line tests. 
Patients with positive urine cytology as the only finding underwent further cystoscopy, 
retrograde studies or ureteroscopy with biopsy under general anaesthetic. Outcome in 
terms of eventual diagnosis were cross-referenced with initial urine cytology results 
(classified as malignant, suspicious, atypical, benign or unsatisfactory). Cost of urine 
cytology was calculated.   
Results: 124 (4·5%) patients had malignant cells and 260 (9·4%) atypical/ suspicious. For 
urothelial cancer cytology demonstrated 45·5% sensitivity and 89·5% specificity. Two 
patients with urine cytology as the only positive finding had urothelial malignancy on 
further investigation. For the entire cohort, cost for cytology was £111,120.  
 
Conclusions: Routine urine cytology is costly and of very limited clinical value as a first 
line investigation for all patients with haematuria and should be omitted from guidelines.
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Introduction: 
Urine cytology has been a standard haematuria investigation for many years, 
recommended by major guidelines including the American Urological Association and 
the European Association of urology.
1,2
  Validity of routine urine cytology in the routine 
investigation of haematuria has been questioned due to several shortcomings and it is 
doubtful if it adds any benefit beyond other standard investigations.
3,4 
Standard haematuria investigations include upper tract imaging and cystoscopy. 
Depending on available resources, upper tract imaging may include ultrasound (U/S) and 
subsequent intravenous urography (IVU) or CT urogram (CTU) if necessary. It has been 
recognised for many years that urine cytology is an operator dependent investigation.
5
 
Interpretation of the characteristics of voided transitional cells does not just depend on 
the operator but also on the method and timing by which urine cytology has been 
collected.
6
 Urine cytology has high specificity of 90-100%
6–8
 but a sensitivity that is 
significantly dependent on the grade of the tumour. Sensitivity rates can be 20%, 45% 
and 75% for G1, G2 and G3 tumours respectively.
8–10
 The variability in the sensitivity 
rates may be due to inter-observer discrepancy in analysis and sampling.
11 
Urine cytology has a low false positive rate of 1-12% but this may lead to further 
invasive investigations such as ureteroscopy.
12
 The false positive rate is dependent on 
whether atypia and suspicious samples are included. These changes are common in a 
variety of benign disorders and after instrumentation of the urinary tract. Low sensitivity 
in low grade tumours invalidates its use as a cost-effective screening test in general 
unless its use is restricted to individuals at high risk of having the disease.
13 
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The estimated cost of a single urinary cytology test is reportedly variable ranging from 
£22-163.
3,8,14,15
 In the UK, the most expensive estimate within the context of the National 
Health Service (NHS) is £92.
8
 Urine cytology has to be sent before cystoscopy to avoid 
distortion of the cells by instrumentation. Urine cytology was sent from the haematuria 
clinic even if an obvious pathology is found. In an era when resources are limited, the 
additional costs of cytology in the initial assessment of haematuria should be evaluated. 
 
Materials and Methods 
2778 consecutive patients were prospectively studied from January 1999 to September 
2007. The data set included age, sex, smoking, visible haematuria (VH) or non-visible 
haematuria (NVH). NVH patients underwent U/S scan of the renal tract and flexible 
cystoscopy. VH patients underwent ultrasound scan of the renal tract and flexible 
cystoscopy and IVU or CTU to complete the investigations. Voided urine cytology was 
routinely submitted for all patients and was collected prior to flexible cystoscopy. 
Flexible cystoscopy was performed by a Urology Consultant, senior trainee or nurse 
specialist. Follow-up of all patients was done through the pathology database in 2010 
by identifying patients who had tumor identified after initial evaluation of 
hematuria.   
Data analysis was completed in October 2010. Main outcomes analysed were the results 
of the investigations which included cystoscopy, U/S, cytology and, when done, 
IVU/CTU in terms of establishing a diagnosis of urothelial malignancy. Cytology 
findings were recorded as malignant cells identified, atypical/suspicious cells identified, 
unsatisfactory specimen or cytology not recorded. Atypical/suspicious results had repeat 
 6 
urine cytology until yielding a “no malignant cells” identified result. Pathology reporting 
was performed by one single pathologist with an interest in uro-oncology in accordance 
with universally adopted protocols (WHO grading of urothelial neoplasms). Pathological 
reports from any initial procedure were collected and follow-up was undertaken on all 
patients to identify any significant recurrences. The utility of urine cytology as a test was 
assessed by calculating its sensitivity, specificity, negative predictive value, positive 
predictive value, false negative rate and false positive rate. Statistical analyses were 
carried out using the SPSS (Statistical Package for the Social Sciences) version 17·0 
software. 
 
Results 
The patient cohort included 1867 men and 911 women (M:F=2:1) with 1804 presenting 
with VH and 974 with NVH. Of the VH group 382 (21·2%) harboured a urological 
malignancy, the majority of these (87%) had a bladder tumour. Of the NVH group 45 
(4·6%) harboured a urological malignancy, the majority of these (93%) had a bladder 
tumour (Table1). Mean follow-up (+/- standard deviation) was 7.3 (+/- 2.4) years. 
Median follow-up was 7.3 (range 2.9 – 11.6) years. Data analysis was completed in 
October 2012.  
Regarding cytology results, 124 (4·5%) patient samples returned with malignant cells. A 
further 260 (9·4%) showed atypia or were classified as suspicious for malignancy. 
Cytology was negative in 2123 (76·4%) of patients. 207 (7·5%) had no urine sample sent 
from haematuria clinic. In 64 (2·3%) patients the specimen was unsatisfactory for 
analysis (Table 2). Four patients with malignant cytology had no diagnosis found. 
One hundred and twenty five patients with atypical/suspicious cytology had no 
diagnosis found. 
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For the analysis of utility of urinary cytology as a test for detecting urothelial carcinoma, 
suspicious and atypical cytology are included along with malignant samples. Patients in 
whom urine samples were not sent or in whom the specimen was unsatisfactory were 
excluded from the analysis. The sensitivity for diagnosing urothelial carcinoma was 
45·4% and the specificity was 89·5% (Table 3). The false positive rate was 10·5%, false 
negative rate was 54.6%, positive predictive value was 40.9%, and negative predictive 
value was 89·5%. 
Of all 2778 patients only two had a negative cystoscopy, ultrasound and IVU with a 
positive cytology that was eventually diagnosed as urothelial carcinoma. The first case 
had cystoscopy that reported inflammation of unknown cause which should have 
warranted biopsies. This was not done but positive cytology returned and the subsequent 
biopsies showed TCC with carcinoma in-situ. The second case had intermittent positive 
cytology and VH over the course of a year which prompted progressive investigations. 
Initial cystoscopy/ultrasound and IVU and CTU were negative. The patient then had 
bilateral retrogrades studies were unremarkable. However, subsequent bilateral diagnostic 
ureteroscopy revealed a right ureteric TCC (T1G3). 
  
Discussion: 
Urine cytology lacks sensitivity for low and intermediate grade superficial tumours which 
represent the majority of transitional cell carcinoma. In this study more than 85% of 
tumours were either G1 or G2. There have been attempts to create new useful urinary 
tests with higher sensitivity than cytology that would be an improvement on cytology for 
haematuria investigation and cancer surveillance. A systematic review showed that 
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involving cytology was considered to be the least worthwhile.
8
 Cytology followed by 
white light cystoscopy in initial diagnosis and follow-up is likely to be the least costly 
(£1043 per patient) but it was also the least effective in terms of life-years (11·6) per 
patient.
8
 The review suggested the use of other urinary biomarkers along with 
photodynamic diagnosis (PDD) was the most effective albeit having higher cost 
associated with it (£2370 per patient and 11·7 life-years). With its increasing use in 
clinical practice, the use of urine cytology is perhaps going to be even less useful.
8
 Other 
promising tests are Nuclear Matrix protein-22 (NMP22), ImmunoCyt and Flouresence in-
situ hybridisatin (FISH). Elevated levels in urine can be detected with excessive cell 
division seen in transitional cell carcinoma.
16
 NMP22 has been developed into a point-of-
care bedside test without requiring laboratory evaluation. As with other biomarkers it is 
more sensitive than cytology but less specific since it is elevated in other benign bladder 
disorders. ImmunoCyt is an immunocytological fluorescence assay designed to improve 
the sensitivity of lower grade tumours by combination with cytology.
17
 It therefore 
carries the same problems of subjectiveness due to operator dependence and is even more 
expensive than cytology alone. In addition its use lowers the specificity of cytology. 
FISH (known commercially as UroVysion), is based on the inspection of transitional cell 
chromosomes for genetic alterations commonly present in bladder cancer. This time-
consuming, expensive test requiring trained personnel has specificity second only to 
cytology.
8,18
 Due to its technique of examining the cell nucleus, it has been suggested that 
FISH may detect tumours that are undetectable macroscopically on cystoscopy.
19
 The 
cost of NMP22, Immunocyst and FISH are £39·30, £54.80 and £54·8 respectively.
8
 This 
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does not include labour which may double these figures. The ideal urinary biomarker has 
not been found to date. 
Other studies with smaller patient cohorts presenting with haematuria have published 
similar findings in regard to the extremely small number of patients in whom urine 
cytology diagnosed urothelial cancers which would otherwise have been missed by other 
investigations such as flexible cystoscopy and upper tract imaging.
3,4,11,14
 Consequently it 
is highly unlikely that the benefits of cytology will outweigh its costs in the context of its 
use on patients presenting with haematuria. We no longer use routine cytology for 
haematuria investigation. Urine is sent for cytology only if no pathology is found at 
cystoscopy. 
The cost of cytology is difficult to estimate being an operator-dependent investigation, 
merely using the cost of the cytology equipment would underestimate this. The official 
United Kingdom NHS estimate is £92
8
 but this is significantly more than other European 
estimates in other literature. This is in the region of £30-40.
3,14,15
   
Continuing use of cytology in the current manner i.e. for all patients at initial 
presentation, there are significant costs. The estimated costs associated with performing 
urinary cytology on 2778 patients at £40 each was approximately £111,120. In addition 
there are costs associated with false positives at the rate of 10.5%; these are incurred by 
way of further invasive endoscopic assessment, repeat cytology and radiological upper 
tract imaging. These have been estimated at approximately £12,000 per patient on 
average.
3
 Costs must be balanced against the benefits of diagnosing urothelial carcinoma 
which were missed through other routine tests. A systematic review on economic 
evaluation suggests that urine cytology has no application in ruling out malignancy or 
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excluding patients from further investigation. Furthermore it mentions that neither 
tumour markers nor urine cytology can currently be used alone to rule out malignancy or 
to rule out patients from further investigation.
20
  In this study, only 2 out of 2778 patients 
benefited from urine cytology. Limitations of the study include the non-inclusion of 
those cytology specimens which were unsatisfactory for analysis or where the urine 
cytology results have not been recorded. 
 
Conclusions: 
Guidelines for the routine use of urine cytology should be revised. When used in 
conjunction with cystoscopy and upper tract imaging in the investigation of patients 
presenting for the first time with haematuria, urine cytology adds very little to the 
diagnostic value of standard haematuria investigations. On the contrary, urine cytology is 
associated with relatively high costs and can potentially result in additional expensive and 
morbid investigations because of false positives. The routine use of urine cytology is of 
limited value and should not be included in guidelines. 
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Table 1 
Cancers found in Haematuria Clinic (NVH= Non-visible Haematuria, VH = Visible 
haematuria, >40: age more than 40 years, <=40: age less than or equal to 40 years) 
 
Diagnosis NVH 
n = 974 
VH <= 40 
n = 190 
VH > 40 
n = 1614 
Bladder cancer 42 (4.3%) 5 (2.6%) 329 (20.3%) 
Renal cancer 3 (0.3%) 1 (0.5%) 39 (2.4%) 
Renal TCC 0 0 8 (0.5%) 
Urothelial melanoma 0 0 1 
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Table 2 
Cytology findings in Haematuria Patients 
 
Cytology No Path Bladder 
Ca 
UT TCC RCC Benign All (%) 
Clinical findings 
Malignant Cells 4 93 3 2 22 124 (4·5%) 
Atypical/suspicious 125 60 1 6 68 260 (9·6%) 
No Malignancy 1362 185 4 33 539 2123 (76·4%) 
Unsatisfactory 57 6 0 1 0 64 (2·3%) 
Not Recorded 153 32 0 1 21 207 (7·5%) 
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Table 3 
Utility analysis of urine cytology (TCC: Transitional cell carcinoma) 
 
Cytology/Diagnosis No TCC TCC Total 
No malignancy 1934 189 2123 
Malignant or 
atypical/suspicious 
227 157 384 
Total 2161 346 2507 
 
Sensitivity = 157/346 = 45·4% 
Specificity = 1934/2161 = 89·5% 
False positive rate = 227/2161 = 10·5% 
False negative rate = 189/346 = 54·6%  
Positive predictive value = 157/384 = 40·9% 
Negative predictive value = 1934/2161 = 89·5% 
 
